- Home
- CLDX vs NNNN Comparison
CLDX vs NNNN Comparison
Compare CLDX & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- NNNN
- Stock Information
- Founded
- CLDX N/A
- NNNN 2021
- Country
- CLDX United States
- NNNN Germany
- Employees
- CLDX N/A
- NNNN N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CLDX Health Care
- NNNN Health Care
- Exchange
- CLDX Nasdaq
- NNNN Nasdaq
- Market Cap
- CLDX 1.9B
- NNNN 2.2B
- IPO Year
- CLDX 2008
- NNNN 2025
- Fundamental
- Price
- CLDX $24.34
- NNNN $22.23
- Analyst Decision
- CLDX Buy
- NNNN
- Analyst Count
- CLDX 10
- NNNN 0
- Target Price
- CLDX $43.80
- NNNN N/A
- AVG Volume (30 Days)
- CLDX 866.0K
- NNNN 38.1K
- Earning Date
- CLDX 11-10-2025
- NNNN 04-28-2026
- Dividend Yield
- CLDX N/A
- NNNN N/A
- EPS Growth
- CLDX N/A
- NNNN N/A
- EPS
- CLDX N/A
- NNNN 0.06
- Revenue
- CLDX $2,599,000.00
- NNNN $8,185,146.00
- Revenue This Year
- CLDX N/A
- NNNN N/A
- Revenue Next Year
- CLDX N/A
- NNNN N/A
- P/E Ratio
- CLDX N/A
- NNNN $399.17
- Revenue Growth
- CLDX N/A
- NNNN 21.95
- 52 Week Low
- CLDX $14.40
- NNNN $5.18
- 52 Week High
- CLDX $29.05
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- CLDX 44.59
- NNNN 48.30
- Support Level
- CLDX $22.10
- NNNN $12.93
- Resistance Level
- CLDX $26.85
- NNNN $25.20
- Average True Range (ATR)
- CLDX 1.20
- NNNN 4.22
- MACD
- CLDX -0.30
- NNNN 0.79
- Stochastic Oscillator
- CLDX 36.70
- NNNN 79.82
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.